Healthcare Industry News: HSMN NewsFeed
News Release - March 9, 2018
Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly OncologyINDIANAPOLIS, March 9, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that Maura Dickler, M.D., a prestigious breast cancer researcher, will join Lilly Oncology as Vice President of Late Phase Development on May 7, 2018.
Dr. Dickler is currently the Section Head, Endocrine Therapy Clinical Research Program at Memorial Sloan Kettering Cancer Center (MSKCC). She concurrently serves as Associate Member, Breast Medicine Service, Department of Medicine, MSKCC and Associate Professor of Medicine, Weill Cornell Medical College, NY. She will report to Levi Garraway, M.D., Ph.D., Senior Vice President, Global Development & Medical Affairs of Lilly Oncology.
"Dr. Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities," said Garraway. "Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr. Dickler join us at Lilly."
About Maura Dickler, M.D.
Dr. Dickler graduated from The University of Chicago's Pritzker School of Medicine and completed her fellowship at MSKCC. She is a clinical researcher on the Breast Medicine Service at MSKCC, with a research program focused on developing new therapeutic strategies for the treatment of women with hormone-receptor positive (HR+) breast cancer. She has led clinical trials investigating therapeutic agents targeting several growth factor receptor-signaling pathways important in breast cancer, including the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor (VEGFR), phosphoinositide 3-kinase (PI3K) and the estrogen receptor pathway. She has also investigated cyclin-dependent kinase 4 & 6 (CDK4 & 6) inhibitors targeting the cell cycle.
Dr. Dickler's research and clinical accomplishments have led to numerous publications and she has served on various committees including the Breast Committee of The Alliance for Clinical Trials in Oncology. She has received honors for her clinical care, including New York Magazine's Best Doctors, Medical Oncology in 2015, 2016 and 2017; Castle Connolly America's Top Doctors; and Castle Connolly Exceptional Women in Medicine in 2017.
About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly's commitment to people with cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsLilly Completes Acquisition of ARMO BioSciences
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression